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ETS factors havebeenshown tobedysregulated in breast cancer. ETS factors control the expression of genes involved
in many biological processes, such as cellular proliferation, differentiation, and apoptosis. FLI1 is an ETS protein
aberrantly expressed in retrovirus-induced hematological tumors, but limited attention has been directed towards
elucidating the role of FLI1 in epithelial-derived cancers. Using data mining, we show that loss of FLI1 expression is
associated with shorter survival and more aggressive phenotypes of breast cancer. Gain and loss of function cellular
studies indicate the inhibitory effect of FLI1 expression on cellular growth, migration, and invasion. Using Fli1 mutant
mice and both a transgenicmurine breast cancermodel and an orthotopic injection of syngeneic tumor cells indicates
that reduced Fli1 contributes to accelerated tumor growth. Global expression analysis and RNA-Seq data from an
invasive humanbreast cancer cell linewith over expressionof either FLI1 and another ETSgene, PDEF, shows changes
in several cellular pathways associated with cancer, such as the cytokine-cytokine receptor interaction and PI3K-Akt
signaling pathways. This study demonstrates a novel role for FLI1 in epithelial cells. In addition, these results reveal that
FLI1 down-regulation in breast cancer may promote tumor progression.
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Breast cancer is the second most common cancer-related death among
women in the United States. In 2014, approximately 232,670 women
will be diagnosed with and 40,000 will die from invasive breast cancer
[1]. Most breast cancer-related deaths are due to metastatic progression,
as cells migrate from the primary tumor, invade, and re-establish at
distant sites [2]. With conventional chemotherapies and radiation
having minimal effect, metastatic breast cancer is generally incurable
[3]. This failure is, in part, due to the fact that breast cancer is not a
single disease, but a heterogeneous disease associated with variations in
gene expression that misdirect the cancer cell to invade and migrate
[3,4]. This transcriptional activation or repression of cancer-associated
genes is not clearly understood; however, many ETS family members
function as oncogenes or tumor suppressors.
ETS transcription factors are highly conserved proteins with a unique
wingedhelix-turn-helixDNA-bindingdomain.Theseproteins recognize a core
5′-GGA(A/T)-3′ sequence present in downstream target genes. ETS factors
activate or repress genes involved in various biological processes, including
cellular proliferation, differentiation, transformation, and apoptosis [5].
Several ETS factors are dysregulated in breast cancer: ETS1 and ETS2
are both up-regulated in breast cancer [6,7]. PEA3 levels are positively
associated with HER2/neu overexpressing human breast tumors [8]. The
related PEA3 family gene, ERM is positively correlatedwith EGFRpositive
breast cancer and with poor overall survival [9]. ESE1 mRNA is
overexpressed in DCIS, an early stage of human breast cancer [10]. In
contrast, prostate-derived ETS factor (PDEF) is reduced in human invasive
breast cancer tissue and absent in invasive breast cancer cell lines [11–13].
Friend leukemia virus integration 1 (FLI1) is a member of the ETS
family, initially identified as a proto-oncogene as it is aberrantly-
expressed in retrovirus-induced hematological tumors in mice [14]. In
humans, FLI1 is rearranged in Ewing's sarcoma and related primitive
neuroectodermal tumors characterized by a t(11;22)(q24;q12) translo-
cation [15]. FLI1 is essential for embryonic development as its loss
results in embryonic lethality due to the absence of megakaryocytes and
aberrant vasculogenesis [16–18]. In normal adult tissues, FLI1 is
expressed in hematopoietic cells and tissues, endothelial cells and
fibroblasts[16,17,19] and along with GATA-1, has a critical role in the
regulation of megakaryocyte differentiation [20]. In endothelial cells,
FLI1 is important in vascular integrity regulates several vascular
homeostasis genes such as VE-cadherin, PECAM1, PDGFB, and SIP1
receptor [21]. In fibroblasts, the loss of FLI1 results in an increase of
collagen type I and a decrease in MMP1, thus contributing to the
development of fibrosis [22,23]. FLI1 regulates numerous biological
processes in a number of different tissue types; however, limited
attention has been directed towards elucidating the potential role of
FLI1 in epithelial-derived cancers, including breast cancer.
In this study, we demonstrate that FLI1 is expressed in normal, and
decreased in human and mouse mammary tumor tissue and human
breast cell lines. Modulation of expression of FLI1 in breast cell lines and
animal tumor models alters cell growth, migration, and invasion. Gene
expression profiling using RNA-Seq identifies several cellular pathways
modified by FLI1 over expression. The results of these experiments
provide evidence for a novel and significant role for FLI1 in breast cancer.Materials and Methods
Cell Culture
Human breast epithelial cell lines were maintained at 37°C with
5% CO2 in medium supplemented with 10% fetal bovine serum and100 units penicillin/streptomycin. All cell lines were grown as
recommended by their source. MCF-10A and MCF-12A were grown
in DMEM/F12 with 5% horse serum, 100 U penicillin/streptomycin,
EGF (20 ng/ml), insulin (10 μg/ml), cholera toxin (100 ng/ml), and
hydrocortisone (0.5 μg/ml). The breast cancer cell lines CAMA-1,
HBL-100, BT-474, andMDA-MB-175VII were a kind gift of R. Neve
(Cancer Research Institute, University of California, San Francisco, CA;
Lawrence Berkeley National Laboratory, Berkeley, CA), the MCF-10A
cell line was a kind gift from B. Toole (Medical University of South
Carolina, Charleston, SC), and the MCF-12A cell line was a kind gift
from A. Gutierrez-Hartmann (University of Colorado Health Sciences
Center, Denver, CO). All other lines were obtained from ATCC.
During the course of the experiments described herein, all of the breast
cell lines have maintained consistent morphology, doubling times, and
tested negative for mycoplasma. MCF-10A and MDA-MB-231 were
authenticated in July, 2011 at the Genetics Resource Core Facility at
The Johns Hopkins University by using the Power Plex 1.2 system
described (http://faf.grcf.jhmi.edu/str.html).
Data Mining
To determine the FLI1 mRNA expression levels in human breast
tumors, FLI1 expression values were extracted from the public Gene
Expression Omnibus data repository (GEO, http://www.ncbi.nlm.
nih.gov/geoprofiles/) [24]. A microarray dataset of 60 micro-dissected
estrogen receptor (ER) positive primary breast tumors was selected
based on the large sample size [25]. The resulting profile displays the
expression level of FLI1 across all samples within DataSet Record
GDS807. FLI1 expression values in human breast tumors were also
extracted from public datasets from Oncomine 4.4 Research Edition
(Compendia Bioscience, Ann Arbor, MI). To find the resulting
dataset the following filters were used: Gene: FLI1; Analysis Type:
Cancer vs. Normal; Cancer Type: Breast. The data sets were ordered
by under-expression: p-values and the datasets selected for analysis
and visualization were the top two with the most significant P values
(Zhao Breast and Richardson Breast 2) [26,27]. Expression levels of
FLI1 in 1881 breast cancer samples, broken down into subtypes, and
51 breast cancer cell lines was obtained from the online tool GOBO,
Gene expression-based Outcome for Breast cancer Online (http://co.
bmc.lu.se/gobo) [28]. In addition, GOBO was used to assess relapse
free survival and overall survival based on expression level of FLI1 in
these tumors as well as co-expressed gene pathways [28].
Immunohistochemistry
Tissue microarray slides were obtained through Imgenex
(San Diego, CA) from SuperBioChips in Korea (Imgenex is their
US distributor) (http://www.tissue-array.com/ver3/index.php) and
were collected under discarded tissue protocols (tissue in excess of that
needed for diagnosis). Additional human breast cancer samples were
obtained from the Pathology Department at the Medical University
of South Carolina (MUSC, Charleston, SC). These tissues were
obtained from consented patients who agreed to have material not
needed for pathological diagnosis be available for research purposes.
Specimens were provided under an Exempt IV research MUSC IRB
for human research (HR 19968, DKW).
All of the specimens were formalin-fixed and paraffin-embedded.
Antigen retrieval and immunohistochemical staining were performed
as previously described; however, NovaRed was used for the substrate
[12]. Anti-FLI1 antibodies, previously prepared [29], were used at
1:800 dilution. All of the sections were examined independently by a
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positive when the FLI1 signal was observed in the cell nuclei. The
overall IHC score was calculated by multiplying the staining intensity
(0 to 4+) by the % of positive cells [IHC score =Σ(intensity) × %
positive cells]. Images were taken at 40× using a Nikon Eclipse 90i
upright semi-automated microscope with a Nikon DS-Fi1 camera.
Mouse tumor and lung tissue sections were processed as above
and stained with antibodies recognizing Ki67 (Thermo Scientific,
Waltham,MA), CD31 (Abcam, Cambridge, UK) and activated Caspase
3 (Cell Signaling, Beverly, Massachusetts). Quantification of staining for
Ki67 was determined by counting of individual stained cells in five 40×
field. For CD31, quantification was determined by counting the number
of vessels per field, measuring the length of vessels and area of field
occupied by stained vessels using ImageJ. Activated caspase-3 was
quantified by counting individual positively stained cells per 20× field.
Western Blot
Cells were lysed in radioimmunoprecipitation assay buffer (5mMTris
pH 8.0, 1% NP40, 0.15 M NaCl, 0.1% SDS, 0.5% Na-deoxycholate)
containing protease inhibitor cocktail (Pierce, Rockford, IL). Equal
amounts of protein were resolved by SDS-PAGE and subjected to
Western blot analysis using enhanced chemilluminescence (Pierce).
Rabbit polyclonal antibody against FLI1, previously prepared [29], was
used at a 1:1000 dilution. Anti-FLAGM5monoclonal antibodywas used
at a 1:500 dilution (Sigma-Aldrich, St. Louis, MO). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) rabbit polyclonal antibody
(Abcam, Cambridge, MA) was used at a 1:1000 dilution. Secondary
anti-Rabbit andMouse IgG (GEHealthcare, Piscataway, NJ) were used
at a 1:2000 dilution.
Reverse Transcription and Real-Time PCR
RNA extraction, reverse transcription, and real-time PCR were
performed as previously described[30]. Primer sequences and probe
numbers are described (Supplementary Table SI).
Adenoviral Infection
The construction of FLI1-expressing and PDEF-expressing
adenovirus has been previously described [12,31]. Cells were
infected in normal growth medium using the lowest dilution of
either control virus expressing green fluorescent protein (Ad-GFP) or
virus expressing FLI1/GFP (Ad-FLI1) or PDEF/GFP (Ad-PDEF)
that yielded N95% infected MDA-MB-231 cells assessed by
GFP expression. Infected cells were then incubated as normal for
16 to 20 hours.
shRNA Design and Transduction
Five lentiviral transduction particles encoding for shRNA against FLI1
were purchased from Sigma-Aldrich. These five 21-nucleotide shRNA
duplexes targeting five different regions of the human FLI1 mRNA
(GenBank accession number NM_002017) were designed using the
MISSION search database (www.sigma-aldrich.com/missionsearch).
The shRNA sequences tested are presented in Supplementary Table
SII. MCF-10A cells were transduced with lentivirus, either FLI1 shRNA
or non-targeting control, following the manufacturer's protocol.
Transduced cells were selected in puromycin-containing (2 μg/ml) cell
culture medium. Viable cells from the 96-well plates were expanded and
maintained in media containing 1 μg/ml puromycin. Inhibition of FLI1
protein expression was determined byWestern blot analysis. Two of the
five sequences were selected for biological assays.Plasmid Transfection
FLI1 cDNA was subcloned into pFcDNA3.1, as previously described
[31]. MCF-10A cells stably transfected with FLI1 shRNA were transiently
transfected with either FLI1 expressing pFcDNA3.1 or control pFcDNA
using FuGENE HD (Roche), per manufacturer's protocol.
Cell growth assays
Cell counts and viability measurements were performed using the
Countess optics and image automated cell counter (Invitrogen,
Carlsbad, CA) using standard trypan blue staining. Floating and
attached cells were combined to obtain numbers of apoptotic and
viable cells.
Transwell Migration and Invasion Assays
Treated or untreated control cells were seeded in triplicate into the
upper chamber of a Transwell insert (BD Biosciences, San Jose, CA)
in 0.1% serum or serum-free medium (MCF-10A or MDA-MB-
231; respectively) at a density of 50,000 cells per well. For migration
assays, inserts were pre-coated with 5 μg/mL fibronectin (Fisher
Scientific, Pittsburgh, PA). Medium containing 0.5% or 10% serum
(MCF-10A or MDA-MB-231; respectively) was placed in the lower
chamber to act as a chemo-attractant, and cells were further
incubated for 6 or 12 hours. (MDA-MB-231 or MCF-10A;
respectively). Cells were counted in 10 random microscope fields
in three independent inserts. Error bars represent the SD from three
separate experiments. Invasion assays were performed as for the
migration assays described above, except inserts were pre-coated with
the extracellular matrix (ECM) substitute Matrigel (BD Biosciences)
and incubated over a 24-hour period. Incubation times were chosen
so that cell proliferation would not affect the number of cells
invading or migrating.
Animals and Syngeneic Cell Lines
FVB/N-Tg(MMTV-PyVT)634Mul/J mice (PyVT) were obtained
from Jackson Laboratory (Bar Harbor, ME) [32] and crossed to wild-
type FVB/N and Fli1 heterozygous (FVB/N bkg; NN8) mice [17].
Mice were housed and handled according to approved Institutional
Animal Care and Use Committee protocols. PyVT positive animals
were identified by PCR and gel electrophoresis using primer
sequences and protocol from Jackson Laboratory. Females were
palpated biweekly beginning at 6 weeks of age for tumor formation.
The first tumor palpated was measured biweekly (volume = width2 ×
length) until it reached 2 cm3 volume at which time the mouse was
sacrificed. At sacrifice, total tumor burden was determined, tumor
tissue and lungs were fixed for paraffin embedding and lung, liver,
kidney, and spleen tissue was snap frozen for RNA. The EO771 cells
[33] were obtained from Dr. Ratna B. Ray, PhD., Saint Louis
University [34]. 5 × 105 cells were injected into the left inguinal
mammary gland (#4) of a female wild-type C57BL6 mouse. The
tumor was harvested three weeks post injection, cells were dispersed,
cultured for 48 hours in DMEM with 20% FBS and frozen. These
1× in vivo passaged cells were then used for the following
experiments: EO771 cells (5 × 105) were injected into the left
inguinal mammary gland (#4) of wild-type C57BL6, Fli1 (C57BL6
background) heterozygous or Fli1ΔCTA/ΔCTA females. The mammary
gland was palpated and measured biweekly until the tumor reached a
volume of 2 cm3 or the animal showed distress. The mice were
sacrificed, tumor, and lung tissue were fixed for paraffin embedding
and snap frozen.
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RNA was isolated from Ad-GFP, Ad-FLI1, and Ad-PDEF infected
MDA-MB-231 breast cancer cells and 100–200 ng of total RNAwas used
to prepare RNASeq libraries using the TruSeq RNA Sample Prep Kit
following the protocol as described by the manufacturer (Illumina, San
Diego, CA). A bioinformatic pipeline based upon the Tuxedo pipeline [35]
was developed to process the RNA-Seq data on a local instance of a Galaxy
Project server [36]. Two RNAseq data files, containing forward and reverse
reads, were generated from each of the RNA samples using paired end (PE)
sequencing. FastQC was used to visualize the quality of the sequenced
RNA for each dataset. Each set of PE read files was run through
Trimmomatic [37] to remove low quality base pairs and sequence adapters
(synthetic sequences of DNA that are used to amplify and sequence the
cDNA during RNAseq) using these parameters [ILLUMINACLIP:
TruSeq3-PE.fa:2:30:10 LEADING:3 TRAILING:3 SLIDINGWIN-
DOW:4:20 MINLEN:36]. The Trimmomatic website (http://www.
usadellab.org/cms/index.php?page=trimmomatic) provides detailed infor-
mation on the parameters used.
TopHat 2 (v0.5) [35] was used to map the PE files to the human
genome (hg19) with default parameters. TopHat outputs a binarily
compressed sequence alignment/map (BAM) file containing the
accepted transcript alignments. The aligned transcripts were then
quantified to ascertain gene and isoform expression values using
Cufflinks (v2.1.1) [38] while performing bias correction, quartile
normalization, and multi-read correction. hg19 was used for the
reference genome (FASTA format) and annotation (GTF format). The
assembled isoforms from each of the RNA samples were aggregated
using CuffMerge (v1.0.0) [38] without reference annotation or
sequences. Cuffdiff (v2.1.1) [38] was used to analyze the samples as a
whole, while performing bias correction, quartile normalization, and
multi-read correction. The tool takes as input the aggregated isoforms
GTF file from CuffMerge and the aligned transcript files fromTopHat,
which were specified as being one of two phenotypic groups [39].
Pathway Guide (Advaita, Plymouth, MI) was used to identify the
significant biological pathways using log base 2-fold changes from the
Tuxedo pipeline. The top 20 pathways in PDEF and the top 20
pathways in FLI1 not in the PDEF ranked set were selected for
further evaluation. The union of these two sets of pathways was then
further explored on a per-gene basis. Specifically, given a pathway, the
gene sets in FLI1 were compared to the gene sets in PDEF.
Statistical Analysis
For statistical testing, two-sided paired Student's t tests were performed
using Excel spread sheet for migration/invasion and real-time RT-PCR
assays. Two-way ANOVA tests were done usingGraphPad Prism 4 for cell
viability assays. Error bars represent SDs of three independent experiments,
unless indicated otherwise. Two sided unpaired Student's t test was used to
determine statistical significance of Ki67 and activated Caspase 3 staining.
Survival studies used log-rank (Mantell-Cox) test in Graph-Pad Prism 5.
P values are given for each individual experiment, but in general, P b .05
was considered statistically significant. Tumor growth curves were
analyzed by linear regression and the slopes and y intercepts analyzed to
determine if the lines were different (Graph-Pad Prism 5).Results
FLI1 Levels are Reduced inHuman Breast Cancer and Cell Lines
Gene Expression Omnibus (GEO) [24] and Oncomine databases
were reviewed to determine FLI1 mRNA expression levels in humanbreast tumors. Unpublished microarray data on estrogen receptor
(ER)-positive invasive human breast tumors [25], obtained from
GEO Profiles, demonstrated a decrease in FLI1 expression in 57 of the
60 invasive human breast tumors compared to reference RNA
(Figure 1A) (GEO accession GDS807) [24]. The Oncomine database,
from two additional studies [26,27], again demonstrated that FLI1
mRNA levels are significantly decreased in invasive human breast
tumors (invasive ductal carcinoma; IDC and invasive lobular
carcinoma; ILC) compared to normal breast tissue (Figure 1B).
The GOBO (http://co.bmc.lu.se/gobo) online tool was used to
examine FLI1 expression in 1881 breast cancers from eleven different
studies [28]. Looking at survival from breast cancer, patients with the
lowest third expression level of FLI1 had a shorter overall survival and
shorter relapse-free survival than patients in the middle and highest
expression level of FLI1 (Figure 1C). Comparing FLI1 expression
across different subtypes of breast cancer [40] shows that the more
aggressive subtype, Luminal B, has the lowest FLI1 expression, while
the less aggressive, normal-like subtype has the highest expression of
FLI1 (Figure 1D). FLI1 expression by Breast Cancer subtype is
shown in Supplemental Figure 1.
We next examined FLI1 protein expression by immunohistochem-
istry (IHC). FLI1 protein is expressed in the nuclei of normal human
breast epithelial tissue (Figure 1Ei). However, this expression is decreased
as the tumor progresses from moderately differentiated (Figure 1Eii) to
poorly differentiated invasive breast cancer (Figure 1Eiii). The IHC score
for all 13 samples examined is presented under Figure 1E (T: Tumor; N:
Normal Breast Tissue). Thus, the IHC analysis demonstrates that FLI1
protein is reduced in less well differentiated tumors and supports the
results obtained from the data mining of FLI1 mRNA.
A decrease of FLI1 mRNA and protein was also observed in breast
cancer-derived cell lines. 13 breast cell lines were analyzed and only
three (HBL-100, MCF-10A, and MCF-12A) have significant mRNA
(Figure 1F) and detectable FLI1 protein (Figure 1G). MCF-10A and
MCF-12A are non-transformed, spontaneously immortalized human
mammary epithelial cell lines, whileHBL-100 is an SV40-immortalized
human mammary epithelial cell line. In contrast, FLI1 mRNA and
protein levels were lost or not detectable in the breast cancer-derived cell
lines tested. FLI1 expression was also compared across breast cancer cell
lines separated into subtypes, basal A, basal B, and luminal, and clinical
subtypes, triple negative (TN), Her2 positive (HER2), and hormone
receptor positive (HR) using the GOBO website [41]. Basal A subtype
had the lowest expression of FLI1, while basal B subtype had higher
and luminal intermediate expression (P = 0.00192) (Supplementary
Figure 1). No significant difference was seen between the clinical
subtypes (data not shown).
FLI1 Expression Inhibits Cellular Growth
MDA-MB-231 cells were selected as a model to examine the
functional consequences of FLI1 re-expression. We first determined
if the re-expression of FLI1 impacted viable cell number. MDA-MB-
231 cells infected with Ad-GFP-FLI1 (Ad-FLI1) exhibit a 73% and
65% decrease in viable cells by day three post infection when
compared to parental and Ad-GFP controls; respectively (Figure 2A).
The apoptotic fraction for the parental control and Ad-GFP at 72
hours was 3%, while the re-expression of FLI1 led to an increase in
the percentage of apoptotic cells to 8.3% (Figure 2B). Although
statistically significant, this is not sufficient to explain the effect on
overall cell growth. To better understand the molecular mechanisms
for FLI1-mediated inhibition of cell growth, cell-cycle analysis was
Figure 1. FLI1 expression is reduced in human breast cancer and in breast cell lines. (A) GEO database: FLI1 mRNA levels obtained from 60 ER+
invasive breast tumor samples. GEO accession GDS807 (Ref. 30). (B) Oncomine database: Left, FLI1 mRNA levels from 7 normal breast samples
compared to 40 invasive ductal carcinomas (IDC) (Ref. 31). Right, FLI1 mRNA levels from 3 normal breast samples compared to 35 IDC and 16
invasive lobular carcinomas (ILC) (Ref. 32). (C) GOBOdatabase: overall survival and relapse-free survival for tertiles of FLI1 expression in 1881 breast
tumors. 1+; occasional nucleus 2+ (IHC score: 115, IHC T/N: 33%)) (magnification=400×; scale bar= 50 μm). (D) (E) Relative FLI1 expression in
different subtypes of breast cancer. (F) RT-PCR of FLI1 mRNA from human breast cancer cell lines normalized to GAPDH, (representative of
two independent experiments, run in triplicate). (G) Western blot analysis of FLI1 protein expression levels in human breast cell lines.
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FLI1 (Figure 2C). Compared to uninfected and Ad-GFP infected
cells, the expression of FLI1 did not significantly change the percent
of cells in any of the cell cycle phases.FLI1 Expression Inhibits Migration and Invasion
Wenext determined the effect of FLI1 expression on themotility and
invasiveness of theMDA-MB-231 cells. Compared to both the parental
and Ad-GFP controls, FLI1 expression reduced the number of
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reduced the number of invading cells by 87% (Figure 3B). Therefore,
the re-expression of FLI1 significantly reduces the migratory and
invasive potential of invasive breast cancer cells.
Reciprocal loss-of-function studies were performed by knocking
down FLI1 in MCF-10A cells using two different shRNA lentiviruses
(one targeting the 3′ UTR, shFLI1 #1; the other targets the coding
sequence, shFLI1 #2). Verification of knockdown was determined by
Western blot analysis (Figure 3C), where shFLI #1 had 70% and
shFLI1 #2 had 90% knockdown when compared to parental and short
hairpin control. Compared to both the parental and shRNA controls,
the knockdown of FLI1 expression increased the number of migrating
cells by 48% for shFLI1 #1 and 70% for shFLI1 #2 (Figure 3D). The
knockdown of FLI1 expression also increased the number of invading
cells by 43% for shFLI1 #1 and 71% for shFLI1 #2 (Figure 3E).
To demonstrate that the change in migration and invasion was the
result of knocking down FLI1 and not due to off target effects of the
short hairpin, the MCF-10A cells stably infected with shFLI1 #1 were
transiently transfected with a plasmid vector expressing FLI1. shFLI1
#1 was selected for the rescue experiment due to its target sequence
within the 3′UTR. The re-expression of FLI1 in theMCF-10A shFLI1
#1 cells significantly decreased the number of cells able to migrate and
invade compared to MCF-10A shFLI1 #1 cells transfected with Flag
control (59% and 70% decrease; respectively) (Figure 3E). Taken
together these results suggest that FLI1 contributes to the regulation/of
migration and invasion in breast cell lines.
Fli1 Mutant Mice Demonstrate Enhanced Tumor Growth
Compared to Wild Type Mice
Fli1 knockout mice were created by homologous recombination
[17], backcrossed to FVB/N mice and then crossed to mice expressingFigure 2. FLI1 re-expression inhibits growth of human invasive breas
or cells infected with Ad-GFP or Ad-FLI1, P b .05 by two-way ANOVA.
Ad-FLI1, compared to parental (uninfected) cells. (C) Cell cycle analys
or Ad-FLI1, 36 hours (left) and 72 hours (right) post adenoviral infectithe MMTV-PyVT transgene [32]. The Fli1 homozygous knockout is
embryonic lethal soheterozygous knockoutmicewere compared towild-type
FVB/N mice. Median tumor-free survival was shorter for the MMTV-
PyVT-Fli1 heterozygotes (59.5 days) than the wild type (70 days, P b .03;
Figure 4A). The tumors from the heterozygotes also grew faster (rate of
growth +/− 34.4 mm3/day vs. wt. 26.8 mm3/day; P b .015; Figure 4B).
Overall survival was also significantly different, with median survival for
heterozygous being 102 days vs. 109 for wild type (P b .03) (Figure 4C).
There was no difference in index tumor volume (heterozygotes=2095 +/−
499mm3; wild-type=2039 +/− 412) or total weight of all mammary tumors
(heterozygotes =12 +/− 4.6 g; wild type =12.6 +/− 4.5 g).
No difference was seen in the number of CD31 positive cells/field,
the area of CD31 positive vessels or the length of CD31 positive vessels
between the genotypes of the Fli1 PyVT mice (data not shown). Ki67
staining was higher in the heterozygotes than in wild type. In the
heterozygotes there were 132.4 Ki-67 positive cells per 40× field
compared to 71.5 positive cells in the wild type (Pb .0001) (Figure 4D).
In addition, activated caspase-3 was higher in the heterozygotes than the
wild type. There was an average of 26.1 positive cells in each 20× field
for the wild type versus 117.6 for the heterozygotes (P = .022)
(Figure 4E). The number of lungmetastases was higher in the wild-type
mice but the difference was not significant; however, lung metastases
were larger in the wild-type mice. The total percent area occupied
by metastases in the wild-type lungs was 7.4% versus 1.4% for
heterozygous lungs (P b .05) (Figure 4F). To determine the difference
in Fli-1 protein levels between the two genotypes, the tumors were
stained with FLI1 antibody. Tumor epithelial cells in both wild-type
and Fli1 heterozygous mice were negative for Fli1 staining (Figure 4Gii
and iii). In contrast, normal mammary gland epithelial cells were highly
Fli1 positive (Figure 4Gi). Thus, both wild-type and heterozygous
tumor cells have lost expression of Fli1, in addition, tumor stromal cellst cancer cells. (A) Cell viability assay of parental (uninfected) cells,
(B) Percent of dead cells at 72 hours post infection with Ad-GFP or
is by flow cytometry of parental cells, or cells infected with Ad-GFP
on.*P b .05 by Student's t test.
Figure 3. FLI1 expression inhibits cell migration and invasion. (A and B) Quantification of cells migrated across fibronectin-coated (A) or
matrigel-coated (B) transwells. The columns represent average values of cells migrating/invading as a percentage of parental (uninfected)
cells. (C) Western blot analysis of MCF-10A cells stably infected with either shFLI1 #1 or shFLI1 #2 using anti-FLI1 antibody. (D and E)
Quantification of cells migrated across fibronectin-coated (D) or matrigel-coated (E) transwells. The columns represent average values of
cells migrating as a percentage of parental (uninfected) cells. *P b .05 by Student's t test.
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even lower in heterozygotes (Figure 4Gii).
In order to further evaluate the role of stromal Fli1 in tumor
progression, an orthotopic model of breast cancer was also explored in
two different mutants of Fli1. The EO771 cell line is derived from a
spontaneous mammary gland tumor in a C57BL6 mouse [33]. The
Fli1ΔCTA/ΔCTA mice lack the C-terminal regulatory domain of Fli1
involved in activation or repression of gene transcription, thus affecting a
subset of Fli1 functions. No difference in tumor initiation was seen
between the Fli1ΔCTA/ΔCTA and the wild-type mice; however, the tumor
growth rate was significantly different between the two genotypes
(Figure 5A). The rate of growth for the wild typewas 29mm3/day and for
the Fli1ΔCTA/ΔCTA it was 43 mm3/day (P = .03). Also, the number of
lung metastases was greater in the Fli1ΔCTA/ΔCTA (2.29 +/− 0.78) than in
the wild type (0.25 +/− 0.16; P = .017) (Figure 5B). The EO771 cells
were also orthotopically injected into C57BL6 Fli1 heterozygous mice
and wild-type mice. As with the Fli1ΔCTA/ΔCTA mice, the tumors in
the Fli1 +/− mice grew faster than in the wild type (wild type 52.5 +/−
5 mm3/day; Fli1 +/−, 71.1 +/− 6 mm3/day; P = .02) (Figure 5C) and
survival timewas greater for the wild type (median survival, for wild type =
42 days; for Fli1 +/− = 37 days; P b .05; Log-Rank (Mantell-Cox) test)
(Figure 5D). There was no significant difference in the number or size of
lung metastases, CD31 staining, number of activated caspase-3 positive
cells or number of Ki67 positive cells (data not shown).
FLI1 Modulates the Expression of Genes That Control
Cancer Progression
FLI1 is a transcription factor and its loss in tumors should alter the
expression of many genes contributing to cancer progression. PDEF isanother ETS family member lost in breast cancer [11–13]. Our
laboratory has previously shown that re-expression of PDEF inhibits
proliferation, migration, and invasion [11,12,42]. We have identified
several direct downstream targets of PDEF responsible for tumor
progression. Since FLI1 has similar effects on cellular growth,
migration, and invasion, we examined these downstream effectors
with over expression of FLI1. We selected three candidates: p21,
SLUG and urokinase plasminogen activator (uPA) [12,13,30,43].
Similar to the re-expression of FLI1, an adenoviral delivery system
was used to over-express PDEF in MDA-MB-231 cells and the
Western blot indicates that the infected MDA-MB-231 cell lines both
markedly over express PDEF and FLI1 (Figure 6A). p21 was
increased significantly with the re-expression of FLI1 and PDEF
(88% and 92% increase, respectively when compared to parental)
(Figure 6B). As previously shown [30], PDEF re-expression results in
a decrease in the expression level of SLUG mRNA. However, the
decrease in SLUG expression was not as robust with the re-expression
of FLI1 as was seen with PDEF (FLI1: 46% decrease; PDEF: 86%
decrease when compared to parental) (Figure 6C). The re-expression
of FLI1 did not inhibit the expression of uPA to the extent observed with
PDEF (FLI1: 11% decrease; PDEF: 75% decrease when compared
to parental) (Figure 6D).
FLI1 Targets Cancer Progression by Modulation of
Cancer Pathways
Using the parental and MDA-MB-231 cell lines over expressing
GFP (Ad-GFP), FLI1 (Ad-FLI1), or PDEF (Ad-PDEF), global gene
expression was analyzed using RNA-Seq and our bioinformatic
pipeline. Fold expression compared to Ad-GFP was determined and
Figure 4. Fli1 expression level effects tumor growth and metastases. (A) Tumor-free survival of PyVT wild-type and PyVT-Fli1+/− mice
(Log-Rank test P= .043). (B) Growth of tumors in PyVT wild-type and PyVT-Fli1+/−mice. Significance of the difference between the two
slopes. (p=0.015) (C) Overall survival of PyVT wild-type and PyVT-Fli1+/− mice (log-rank test P = .048) (D) Ki67 staining in tumors from
PyVT wild-type and Fli1+/−mice (P b .0001 by t test). Representative tumor sections stained for Ki67, (scale bar = 250 μm). (E) Activated
caspase-3 staining in tumors from PyVT wild-type and Fli1+/− mice (P b .02). Representative tumor sections stained with antibody to
activated Caspase-3, (scale bar =250 μm). (F) Area of lung metastases from PyVT wild-type and Fli1+/− mice (P = .03). Representative
sections of H&E stained lung lobes (12.5×). (G) Fli1 staining of normal mouse mammary gland (i) and PyVT tumors from wild-type (ii) and
Fli1+/− (iii) (40×) showing loss of Fli1 in tumor cells.
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shows a global representation of the FPKM (Fragments per Kilobase of
transcript perMillion mapped reads) values as a function of the number
of genes in each value. To visualize the difference in expression of
individual genes by either PDEF or FLI1, scatter plots representing the
expression of genes down regulated (Figure 7B) by over expression of
PDEF alone, by FLI1 alone and both and the up regulation (Figure 7C)
of genes compared to GFP were created. Individual genes have been
grouped into categories according to whether or not the fold change
observed in PDEF and/or FLI1 is greater than 2. Genes falling near or
on the line are responding in approximately equal magnitude. A Venn
diagram demonstrates the differences in gene expression caused by FLI1
over expression and PDEF overexpression (Figure 7D). FLI1 expression
uniquely up regulated 274 and down regulated 237 genes. PDEF
expression uniquely increased expression of 1056 genes and decreased
expression of 895 genes. There are 450 genes that are increased by both
FLI1 and PDEF and 215 were decreased by both. 24 genes were up
regulated by either FLI1 or PDEF and decreased by the other treatment.
Log2 values for expression levels of all genes altered either 2 fold up or
down is in supplementary tables IV (PDEF) and V (FLI1).
The RNA-Seq data was downloaded into Pathway Guide (Advaita,
Plymouth, MI) to determine which biochemical pathways were
affected by over expression of either FLI1 or PDEF. Pathway-Guide
incorporates the topology of the pathway into the analysis. Table 1
shows the top 10 pathways for each treatment and where that
pathway ranked in the other treatment group. Also shown are thenumber of genes in each pathway and the number that are changed by
either FLI1 or PDEF or both. The complete Pathway Guide results
are shown in Supplemtary Table III. Many of these pathways are
important to cancer progression, such as cytokine-cytokine receptor
interaction and PI3K-Akt signaling pathways, ranked number 1 and 2
for FLI1, and MAPK signaling pathway and TGF-β signaling
pathway, ranked 1 and 2 for PDEF. A small set of genes in pathways
that were affected by both FLI1 and PDEF were selected for
validation by qPCR. Interleukin 8 (IL8) is a member of the cytokine-
cytokine receptor interaction pathway and the chemokine family. It is
a major mediator of the inflammatory response and a potent
angiogenic factor. It is significantly up regulated by FLI1 over
expression (~10 fold) but is down-regulated by PDEF over expression
(~2 fold) (Figure 7E). In contrast, BIRC2, baculoviral IAP repeat
containing 2, is down regulated by over expression of both PDEF and
FLI1 by approximately 2 fold (Figure 7E). EGF, epidermal growth
factor, is a member of many biological pathways. It is up regulated by
FLI1 (~2-fold) and down-regulated by PDEF (2.5-fold). Other genes
validated by qPCR are CSF1, CTTN, CXCL2, and RELA. All of these
are involved in multiple biological pathways that affect proliferation,
survival and migration, and invasion. All of which are characteristics of
cancer cells.
Discussion
In this study we investigate a novel role for FLI1 in breast cancer.
Most previous studies involving FLI1 used hematopoietic or stromal
Figure 5. Effect of Fli1 genotype on growth of orthotopically injected EO771 cells. (A) Tumor growth in wild-type C57BL6 and Fli1ΔCTA
mice. Dotted lines are actual tumor growth and solid lines are calculated linear regression of tumor growth (significance of difference
between slopes P b .03) (B) Number of lung metastases in EO771 injected wild-type C57BL6 and Fli1 ΔCTA mice (P b .02). (C) EO771
tumor growth in wild-type C57BL6 and Fli1+/− mice. (Significance of difference between slopes P b .02) (D) Overall survival of EO771
injected wild-type and Fli1+/− mice (log-rank P b .05).
Figure 6. FLI1 and PDEFmodulate the expression of genes that control invasion and metastasis. (A) Western blot analysis of parental and
Ad-GFP, Ad-FLI1, or Ad-PDEF infected MDA-MB-231 cells using anti-FLAGM5 antibody. (B) p21 mRNA expression levels in breast cancer
cell lines normalized to S26: control (uninfected) cells, or cells infected with Ad-GFP or Ad-PDEF or Ad-FLI1. (C) qRT-PCR of SLUG and (D)
uPA mRNA expression levels in breast cancer cell lines normalized to S26: control (uninfected) cells, or cells infected with Ad-GFP, Ad-
PDEF, or Ad-FLI1. Each graph is an average of two independent experiments, run in triplicate. * P b .05.
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Figure 7. FLI1 and PDEF modulate the expression of many genes associated with cancer. (A) This plot was created by computing the
frequency density of the FPKM values for each group using the programming language R and the ggplot2 library. An upper limit on the
FPKM (x-axis) was introduced for visibility purposes. (B and C) Plot of the fold change values of PDEF/GFP vs. the fold change values of
FLI1/GFP. Individual points on the graph represent genes, and the genes are subdivided into groups based on whether the fold change
was above 2 in both phenotypes (■) a single phenotype (▼PDEF; ◊FLI1), or neither phenotype (○). Plots were created with the
programming language R using the ggplot2 library. The fold change of FLI1/GFP versus the fold change of PDEF/GFP. Positive fold
changes shown in (B) correspond to increases in expression of treatment (FLI1 and PDEF) versus GFP. Negative fold changes shown in
(C) correspond to decreases in expression of treatment versus GFP. (D) Venn diagram showing the number of genes over or under
expressed in AdPDEF and AdFLI1 treated cells. Italicised numbers are positively altered genes, underlined are negatively altered.
Numbers in each circle are those unique to each cell line. In the center is the number of genes that are either changed in the same
direction by AdPDEF and AdFLI1 or those changed in the opposite direction (grey number). (E) Fold change levels of selected genes
validated by qPCR. Red bars: AdPDEF transfected MDA-MB231. Blue bars: AdFLI1 transfected MDA-MB231.
Table 1. Top ten pathways identified by Pathway Guide for over expression of FLI1 (first 10 rows) and PDEF (second 10 rows).
Pathway FLI1
Rank
PDEF
Rank
Number of
Genes in Pathway
Number of
Significant in FLI1
Number of
Significant in PDEF
Genes Shared Unique
FLI1 Genes
Unique
PDEF Genes
Cytokine-cytokine receptor interaction 1 45 267 40 54 32 8 22
PI3K-Akt signaling pathway 2 25 347 155 177 145 10 32
Toxoplasmosis 3 65 122 32 37 27 5 10
Phosphatidylinositol signaling system 4 1 81 18 26 14 4 12
Proteoglycans in cancer 5 4 226 49 104 44 5 60
Measles 6 35 134 24 34 15 9 19
Salmonella infection 7 94 88 14 13 9 5 4
Focal adhesion 8 3 206 95 110 86 9 24
Pathways in cancer 9 17 327 140 183 123 17 60
Hippo signaling pathway 10 14 156 49 75 46 3 29
MAPK signaling pathway 11 2 260 48 75 39 9 36
TGF-beta signaling pathway 41 5 81 50 59 49 1 10
Gap junction 43 11 89 27 47 25 2 22
Viral carcinogenesis 47 6 207 14 38 10 4 28
Neurotrophin signaling pathway 48 12 120 34 41 28 6 13
P53 signaling pathway 49 8 68 55 58 55 0 3
Estrogen signaling pathway 74 13 100 65 75 64 1 11
Cell cycle 88 9 124 37 62 36 1 26
Insulin signaling pathway 102 10 140 62 86 60 2 26
Fanconi anemia pathway 112 7 54 3 21 2 1 19
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known. Published data on FLI1 and its role in breast cancer
progression is limited. Earlier studies in mice found reduced
FLI1 mRNA and cDNA in mammary tumors compared to normal
tissue and cell lines [44] and in human breast cancer cell lines and
tumor tissue compared to immortalized human breast epithelial cell
lines [45]. Contrary to the above studies, another report found that
the expression of FLI1 contributes to the progression of human breast
cancer by regulating the bcl-2 gene; thus, inhibiting apoptosis [46].
These conflicting results indicate the need for additional biological
studies on the role of FLI1 in breast cancer progression. Our studies
demonstrate that FLI1 is reduced or lost in human breast cancer
tissue; this loss is associated with more aggressive cancer and shorter
survival and leads to an increase in proliferation, invasion, migration,
and metastasis.
Previous studies defined a role for FLI1 in cell growth and
differentiation in erythroleukemic cells. One of these studies
demonstrated that FLI1 binds to an ETS consensus site within the
retinoblastoma (Rb) gene, leading to the transcriptional repression of
Rb and maintenance of cell growth [47]. Other studies in
erythroleukemic cells revealed that FLI1 negatively regulates the
tumor suppressor p53 by directly binding to and up-regulating
MDM2 [48]. These studies suggest that FLI1 may act as an oncogene
by promoting proliferation and attenuating p53 function in hematopoi-
etic cells. In addition, tumor cell formation results from the translocation
associated production of FLI1 chimeric proteins as has been shown for
Ewing's sarcomas (EWS) and related primitive neuroectodermal tumors
(PNET). However, these mechanisms may not apply to epithelial cells.
In the animal models, we show the effect of gene dosage of Fli1
on tumor growth and the expression of proteins associated with
cancer progression, such as Ki67. In the PyVT model, loss of a
single allele of Fli1 in the heterozygotes leads to earlier and
accelerated tumor growth and higher Ki67 expression in the tumor
cells. However, the wild-type mice show larger lung metastases but
no difference in number.
The EO771 cells do not express Fli1, therefore the differences seen
between the wild-type and heterozygous mice are due to intra-
tumoral stromal cells such as fibroblasts and macrophages. Two
different models of in vivo Fli1 manipulation were used for these
studies. The Fli1 heterozygous mice express half the level of Fli1 as
the wild-type mice, while the Fli1ΔCTA/ΔCTA mice completely lack a
functional domain. Both models showed accelerated tumor growth
compared to wild-type mice; however, the Fli1ΔCTA/ΔCTA mice also
demonstrated an increased number of lung metastases, suggesting
that Fli1 activity plays a significant role early in tumor metastasis. Fli1
has been established as a regulator of stromal cell function. Fli1
negatively regulates both α-smooth muscle actin and collagen type 1
both characteristics of activated tumor stroma [23,49]. Fli1 has also
been shown to negatively regulate MMP1, a protein often up regulated
in breast cancer and important for tumor cell invasion [50].
Ectopic expression of FLI1 and PDEF, individually, increase the
level of p21 mRNA; however, this results in a G0-G1 cell cycle arrest
only with PDEF expression [11,51]. Under stress conditions, p21
is activated by p53 leading to cell cycle arrest, but under normal
conditions p21 acts as a cell cycle regulator at the G1/S phase [52,53].
FLI1 inhibits migration and invasion of human breast cancer cells,
similarly to what was observed for PDEF in our previous studies.
However, known PDEF targets, SLUG and uPA, did not have similar
responses when FLI1 was re-expressed [12,13]. These results suggestthat FLI1 is regulating migration and invasion through alternative as
well as overlapping pathways.
To better understand the difference between FLI1 and PDEF
directed gene expression, we performed RNA-Seq using a malignant
human breast cancer cell line (MDA-MB-231) ectopically expressing
either FLI1 or PDEF. Analysis using Pathway Guide ranked the
pathways affected by the over-expression of FLI1 or PDEF (Table 1).
Two of the higher ranking pathways were phosphatidylinositol
signaling (ranked #4 for FLI1 and #1 for PDEF) and proteoglycans in
cancer (ranked #5 for FLI1 and #4 for PDEF). The proteoglycans in
cancer pathway is involved in cell proliferation and cell migration and
invasion, both functions that are modified by FLI1 and PDEF
expression. Phosphatidylinositol signaling affects cell survival, again
effected by FLI1 and PDEF expression. Other high-ranking pathways
for FLI1 expression are Cytokine Receptor Interaction (#1) and
PI3K-Akt Signaling (#2). Both of these pathways influence cell
survival and proliferation. Additional pathways modified by PDEF
are MAPK Signaling (#2) and Focal Adhesion (#3). These pathways
also contribute to cell proliferation and survival. In addition, the Focal
Adhesion Pathway modulates cell motility. Many of the genes with
altered expression are found in multiple pathways, such that altered
expression of a few or a single gene will affect many pathways.
Our study supports a novel role for FLI1 in an epithelial setting.
Loss of FLI1 in the breast epithelial cells has similar effects,
such as increased migration and invasion, as the loss of PDEF.
However, in contrast to PDEF, FLI1 is not restricted to the epithelial
compartment, being expressed in the endothelium and stromal
fibroblasts. Our animal studies show the impact of stromal Fli1
expression and loss. Thus, another focus of future studies will be to
further elucidate the role of FLI1 in the tumor microenvironment,
and its contribution to the aggressiveness of breast cancer. Furthermore,
a greater understanding of how FLI1 regulates cancer progression
in breast cancer cells may reveal downstream effectors that can be used
as novel markers for improved detection or patient diagnosis, and
ultimately serve as unique therapeutic targets.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.08.007.
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